# US 2009/0275597 A1 · Methods of treating cns disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0275597 A1
- Document ID: US20090275597A1
- Status: Published application
- Kind: A1
- Application number: 12/433,928
- Filed: 2009-05-01
- Published: 2009-11-05
- Earliest claimed: 2008-05-02
- Assignees: Forest Laboratories Holdings Limited
- Inventors: Kelly PAPADAKIS; Nika ADHAM; Gary SAMORISKI
- Web page: https://patentgrep.com/patent/US20090275597A1

## CPC

- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/4965: Non-condensed pyrazines
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.

## Claims

### Claim 1

A method of treating a condition selected from mania and bipolar disorder comprising administering to a patient in need thereof a therapeutically effective amount of an NMDA receptor antagonist, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the disorder is mania.

### Claim 3 (depends on 1)

The method of claim 1, wherein the disorder is bipolar disorder.

### Claim 4 (depends on 2)

The method of claim 2, wherein the mania is acute mania.

### Claim 5 (depends on 4)

The method of claim 4, wherein the acute mania is associated with bipolar disorder.

### Claim 6 (depends on 5)

The method of claim 5, wherein the acute mania is associated with bipolar I disorder.

### Claim 7 (depends on 6)

The method of claim 6, wherein the acute mania is associated with bipolar II disorder.

### Claim 8 (depends on 1)

The method of claim 1, wherein the NMDA receptor antagonist is selected from memantine, neramexane and pharmaceutically acceptable salts thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the NMDA receptor antagonist is memantine, or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the NMDA receptor antagonist is memantine hydrochloride.

### Claim 11 (depends on 8)

The method of claim 8, wherein the NMDA receptor antagonist is neramexane, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 9)

The method of claim 9, wherein the NMDA receptor antagonist is neramexane hydrochloride.

### Claim 13 (depends on 9)

The method of claim 9, wherein the NMDA receptor antagonist is neramexane mesylate.

### Claim 14

A method of treating a condition selected from mania, bipolar disorder and schizophrenia, comprising administering to a patient in need thereof a therapeutically effective amount of an NMDA receptor antagonist, or a pharmaceutically acceptable salt thereof, and a compound of formula (I), or a pharmaceutically acceptable salt thereof:
wherein
R1 and R2 are each, independently hydrogen, alkyl, alkenyl, aryl, cycloalkyl, or aroyl, or R1 and R2 form a heterocyclic ring with the adjacent nitrogen atom;
X is O or S; and
n is 1 or 2.

### Claim 15 (depends on 14)

The method of claim 14, wherein the compound of formula (I) is trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea, or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the compound of formula (I) is trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea hydrochloride.

### Claim 17 (depends on 15)

The method of claim 15, wherein the NMDA receptor antagonist is selected from the group consisting of memantine, neramexane and pharmaceutically acceptable salts and solvates thereof.

### Claim 18 (depends on 15)

The method of claim 15, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 15)

The method of claim 15, wherein the NMDA receptor antagonist is memantine hydrochloride.

### Claim 20 (depends on 15)

The method of claim 15, wherein the NMDA receptor antagonist is neramexane, or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 15)

The method of claim 15, wherein the NMDA receptor antagonist is neramexane hydrochloride.

### Claim 22 (depends on 15)

The method of claim 15, wherein the NMDA receptor antagonist is neramexane mesylate.

### Claim 23 (depends on 14)

The method of claim 14, wherein the disorder is mania.

### Claim 24 (depends on 14)

The method of claim 14, wherein the disorder is bipolar disorder.

### Claim 25 (depends on 23)

The method of claim 23, wherein the mania is acute mania.

### Claim 26 (depends on 25)

The method of claim 25, wherein the acute mania is associated with bipolar disorder.

### Claim 27 (depends on 26)

The method of claim 26, wherein the acute mania is associated with bipolar I disorder.

### Claim 28 (depends on 26)

The method of claim 26, wherein the acute mania is associated with bipolar II disorder.

### Claim 29 (depends on 14)

The method of claim 14, wherein the disorder is schizophrenia.

### Claim 30 (depends on 29)

The method of claim 29, wherein the negative symptoms of schizophrenia are treated.

### Claim 31 (depends on 29)

The method of claim 29, wherein the positive symptoms of schizophrenia are treated

### Claim 32 (depends on 29)

The method of claim 29, wherein the cognitive symptoms of schizophrenia are treated.

### Claim 33 (depends on 29)

The method of claim 29, wherein the affective and residual symptoms of schizophrenia are treated.

### Claim 34 (depends on 29)

The method of claim 29, wherein the secondary social and occupational dysfunctions of schizophrenia are treated.

### Claim 35

A pharmaceutical composition comprising
(i) an NMDA receptor antagonist,
(ii) a compound of formula (I), or a pharmaceutically acceptable salt thereof:
wherein
R1 and R2 are each, independently hydrogen, alkyl, alkenyl, aryl, cycloalkyl, or aroyl, or R1 and R2 form a heterocyclic ring with the adjacent nitrogen atom;
X is O or S; and
n is 1 or 2;
and pharmaceutically acceptable salts and solvates thereof, and
(iii) a pharmaceutically acceptable carrier.

### Claim 36 (depends on 35)

The composition of claim 35, wherein the compound of formula (I) is trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea, or a pharmaceutically acceptable salt thereof.

### Claim 37 (depends on 36)

The composition of claim 36, wherein the compound of formula (I) is trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea hydrochloride.

### Claim 38 (depends on 36)

The composition of any one of claims 36, wherein the NMDA receptor antagonist is selected from memantine, neramexane and pharmaceutically acceptable salts thereof.

### Claim 39 (depends on 38)

The composition of claim 38, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

### Claim 40 (depends on 39)

The composition of claim 39, wherein the NMDA receptor antagonist is memantine hydrochloride.

### Claim 41 (depends on 38)

The composition of claim 38, wherein the NMDA receptor antagonist is neramexane, or a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 41)

The composition of claim 41, wherein the NMDA receptor antagonist is neramexane hydrochloride.

### Claim 43 (depends on 41)

The composition of claim 41, wherein the NMDA receptor antagonist is neramexane mesylate.
